http://www.peregrineinc.com/ () —
Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a clinical-stage biopharmaceutical company developing first-in-class monoclonal antibodies for the treatment of cancer and viral infections, today announced that it will report financial results for the first quarter fiscal year 2011 on September 9, 2010 after market and will host a conference call and webcast at 4:30 p.m. EDT (1:30 p.m. PDT). Peregrine's senior management will discuss financial results for the first quarter ended July 31, 2010 of fiscal year 2011 and will review its clinical development programs.
About Peregrine PharmaceuticalsPeregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative monoclonal antibodies in clinical trials for the treatment of cancer and serious viral infections. The company is pursuing multiple clinical programs in cancer and hepatitis C virus infection with its lead product candidate bavituximab and novel brain cancer agent Cotara@. Peregrine also has in-house cGMP manufacturing capabilities through its wholly-owned subsidiary Avid Bioservices, Inc. (www.avidbio.com (http://www.avidbio.com/) ), which provides development and biomanufacturing services for both Peregrine and outside customers. Additional information about Peregrine can be found at www.peregrineinc.com (http://www.peregrineinc.com/) .
